Identification of VDAC1 as a mitochondria-related target of Duchenne muscular dystrophy based on bioinformatics analysis and in vitro experiments
Authors:
- 12 May 2025
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 158, 114836
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Profound cellular defects attribute to muscular pathogenesis in the rhesus monkey model of Duchenne muscular dystrophyCell, 2024
- Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular DystrophyStem Cell Reviews and Reports, 2024
- Targeting NAT10 protects against sepsis-induced skeletal muscle atrophy by inhibiting ROS/NLRP3Life Sciences, 2023
- Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophyMolecular Therapy - Methods & Clinical Development, 2023
- The mitochondrial adenine nucleotide transporters in myogenesisFree Radical Biology and Medicine, 2022
- Duchenne muscular dystrophy is associated with the inhibition of calcium uniport in mitochondria and an increased sensitivity of the organelles to the calcium-induced permeability transitionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- COX6A2 variants cause a muscle‐specific cytochrome c oxidase deficiencyAnnals of Neurology, 2019
- Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid TreatmentThe Journal of Pediatrics, 2017
- Genetics and Emerging Treatments for Duchenne and Becker Muscular DystrophyPediatric Clinics of North America, 2015
- VDAC, a multi-functional mitochondrial protein regulating cell life and deathMolecular Aspects of Medicine, 2010